Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 13/20 | 0.48 |
| ▸ | REN | P00797 | 2/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2910492 | 1.00 | SSTR4 (0.48) | SSTR4RENPDK1CHRNB2CHRNA4 | |
| SCHEMBL22873631 | 1.00 | SSTR4 (0.48) | SSTR4RENPDK1CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL4123580 | 0.98 | SSTR4 (0.47) | SSTR4RENPDK1CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL18399037 | 0.98 | SSTR4 (0.47) | SSTR4RENPDK1CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL18398943 | 0.98 | SSTR4 (0.47) | SSTR4RENPDK1CHRNB2CHRNA4 | |
| SCHEMBL31616040 | 0.89 | SSTR4 (0.42) | SSTR4RENPDK1CHRNB2CHRNA4 | |
| SCHEMBL28784803 | 0.84 | SSTR4 (0.43) | SSTR4REN | |
| SCHEMBL208810 | 0.81 | SSTR4 (0.41) | SSTR4REN | |
| SCHEMBL25262250 | 0.80 | SSTR4 (0.48) | SSTR4REN | |
| SCHEMBL30771989 | 0.80 | SSTR4 (0.41) | SSTR4REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345341-A1 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INT (DE) | 2025-11-13 | — | — | US | disclosed |
| US-20250326771-A1 | PIPERAZINE DERIVATIVES USEFUL IN HIV THERAPY | VIIV HEALTHCARE CO (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250136581-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI SIMRD BIOTECHNOLOGY CO., LTD. (CN) | 2025-05-01 | — | — | US | disclosed |
| CN-115703765-B | Substituted triazole derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119487019-A | Piperazine derivatives for HIV therapy | VIIV保健公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| EP-4385988-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| CN-112888684-B | 4-pyrimidin-5-ylmethyl-morpholine derivatives and their use as medicaments | 勃林格殷格翰国际有限公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2020079040-A1 | 4-PYRIMIDIN-5-YLMETHYL-MORPHOLINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-04-23 | — | — | WO | disclosed |
| WO-2019074810-A1 | INDAZOLYL-SPIRO[2.3]HEXANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2019-04-18 | — | — | WO | disclosed |
| WO-2019074810-A1 | INDAZOLYL-SPIRO[2.3]HEXANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2019-04-18 | — | — | WO | disclosed |
| CN-108137510-A | Compound | 葛兰素史密斯克莱知识产权发展有限公司 | 2018-06-08 | — | — | CN | disclosed |
| WO-2017090743-A1 | NOVEL IMIDAZOLE COMPOUND AND USE THEREOF AS MELANOCORTIN RECEPTOR AGONIST | 田辺三菱製薬株式会社 | 2017-06-01 | — | — | WO | disclosed |
| EP-1322596-B1 | ZWITTERIONIC TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1322596-A1 | ZWITTERIONIC TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-6479518-B2 | PSYCHOLOGICAL DISORDERS | MERCK & CO., INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020042431-A1 | Zwitterionic tachykinin receptor antagonists | MERCK & CO., INC. | 2002-04-11 | — | — | US | disclosed |
| WO-2002024629-A1 | ZWITTERIONIC TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042431-A1 | Zwitterionic tachykinin receptor antagonists | NPY5R, NPY1R, NPY2R | SSTR4 145/4885REN 383/4885PDK1 2703/4885 |
| US-20250345341-A1 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | GRIN2A, GRIN2C, GRIN3A | SSTR4 1749/4885REN 681/4885PDK1 857/4885 |
| US-20250326771-A1 | PIPERAZINE DERIVATIVES USEFUL IN HIV THERAPY | CCR5, THPO, IL5 | SSTR4 4002/4885REN 534/4885PDK1 661/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | SSTR4 710/4885REN 2518/4885PDK1 1969/4885 |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | SSTR4 568/4885REN 853/4885PDK1 1301/4885 |
| US-20250136581-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GABRA5, SLC6A11, GABRA1 | SSTR4 740/4885REN 1002/4885PDK1 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.